SG64897A1 - Composition and method of treating hepatitis c - Google Patents

Composition and method of treating hepatitis c

Info

Publication number
SG64897A1
SG64897A1 SG1996006295A SG1996006295A SG64897A1 SG 64897 A1 SG64897 A1 SG 64897A1 SG 1996006295 A SG1996006295 A SG 1996006295A SG 1996006295 A SG1996006295 A SG 1996006295A SG 64897 A1 SG64897 A1 SG 64897A1
Authority
SG
Singapore
Prior art keywords
thymosin
composition
treating hepatitis
immune system
potentiating
Prior art date
Application number
SG1996006295A
Other languages
English (en)
Inventor
Paul Chretien
Milton Mutchnick
Original Assignee
Alpha 1 Biomedicals Inc
Milton Mutchnick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha 1 Biomedicals Inc, Milton Mutchnick filed Critical Alpha 1 Biomedicals Inc
Publication of SG64897A1 publication Critical patent/SG64897A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Beans For Foods Or Fodder (AREA)
SG1996006295A 1991-09-13 1992-09-08 Composition and method of treating hepatitis c SG64897A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75954491A 1991-09-13 1991-09-13

Publications (1)

Publication Number Publication Date
SG64897A1 true SG64897A1 (en) 1999-05-25

Family

ID=25056052

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996006295A SG64897A1 (en) 1991-09-13 1992-09-08 Composition and method of treating hepatitis c

Country Status (23)

Country Link
US (3) US6001799A (cs)
EP (1) EP0603305B1 (cs)
JP (1) JP3228512B2 (cs)
KR (1) KR100254082B1 (cs)
AT (1) ATE152914T1 (cs)
AU (1) AU667327B2 (cs)
CA (1) CA2119006C (cs)
CZ (1) CZ286827B6 (cs)
DE (1) DE69219782T2 (cs)
DK (1) DK0603305T3 (cs)
ES (1) ES2103966T3 (cs)
FI (1) FI107879B (cs)
GR (1) GR3024025T3 (cs)
HK (1) HK1021687A1 (cs)
HU (1) HU221006B1 (cs)
MX (1) MX9205240A (cs)
NO (1) NO941310D0 (cs)
RO (1) RO111991B1 (cs)
RU (1) RU2104010C1 (cs)
SG (1) SG64897A1 (cs)
TW (1) TW224053B (cs)
WO (1) WO1993005806A1 (cs)
ZA (1) ZA926964B (cs)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (cs) * 1991-09-13 1994-05-21 Paul B Chretien
WO1995011688A1 (en) * 1992-02-06 1995-05-04 Sciclone Pharmaceuticals Method for treating hepatitis b carriers with minimal disease
AU751199B2 (en) * 1992-07-13 2002-08-08 Government Of The United States Of America As Represented By The Secretary Of The Army Composition and method of treating hepatitis B
EP0627930A4 (en) * 1992-07-13 1997-08-20 Kenneth E Sherman COMPOSITION AND METHOD FOR TREATING HEPATITIS B.
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US6200952B1 (en) 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
US5468729A (en) * 1993-10-26 1995-11-21 Alpha 1 Biomedicals Method for treatment of autoimmune hepatitis
DK0731710T3 (da) * 1993-11-05 2003-06-16 Sciclone Pharmaceuticals Inc Fremgangsmåde og præparat til behandling af patienter med inkompenseret leversygdom
JP3837769B2 (ja) * 1995-06-12 2006-10-25 大塚製薬株式会社 抗ウイルス剤
AU722987B2 (en) * 1996-02-28 2000-08-17 Unihart Corporation Pharmaceutical compositions comprising natural human alpha-interferon
PY0111577A (es) 2000-05-23 2017-01-02 Idenix Cayman Ltd Métodos y composiciones para el tratamiento del virus de la hepatitis c
AP2006003708A0 (en) 2000-05-26 2006-08-31 Idenix Cayman Ltd Methods and compositions for treating flavivirusesand pestiviruses
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
WO2002011749A1 (en) * 2000-08-07 2002-02-14 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis c with thymosin, interferon and ribavirin
WO2002044717A1 (en) * 2000-12-01 2002-06-06 Cornell Research Foundation Animal model for flaviviridae infection
RU2211703C2 (ru) * 2001-06-08 2003-09-10 ООО НТЦ "Юпитер-2" Антистрессорное и ноотропное средство с антивирусным и иммуностимулирующим действием
AU2002330154A1 (en) * 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
US20050013801A1 (en) * 2001-10-05 2005-01-20 Hsu Henry H. Methods of treating liver fibrosis and hepatitis c virus infection
IL161603A0 (en) 2001-10-26 2004-09-27 Rhode Island Hospital Thymosin augmentation of genetic immunization
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
WO2003068162A2 (en) * 2002-02-14 2003-08-21 Pharmasset Ltd. Modified fluorinated nucleoside analogues
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN1678326A (zh) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
PT1523489E (pt) 2002-06-28 2014-06-24 Centre Nat Rech Scient Profármacos de nucleósido modificado em 2' e 3' para tratamento de infecções por flaviridae
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
RU2005118421A (ru) 2002-11-15 2006-01-20 Айденикс (Кайман) Лимитед (Ky) 2'-разветвленные нуклеозиды и мутация flaviviridae
PL377287A1 (pl) 2002-12-12 2006-01-23 Idenix (Cayman) Limited Sposób wytwarzania 2'-rozgałęzionych nukleozydów
GB0301879D0 (en) * 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
JP4149296B2 (ja) * 2003-03-26 2008-09-10 株式会社ルネサステクノロジ 半導体記憶装置
BRPI0408892A (pt) * 2003-03-28 2006-04-11 Sciclone Pharmaceuticals Inc uso de timosina alfa 1 para tratar as infecções por arpergillus
PT1613340E (pt) * 2003-03-28 2010-08-19 Sciclone Pharmaceuticals Inc Tratamento de infecções por aspergillus com timosina alfa 1
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
BRPI0419345B8 (pt) 2003-05-30 2021-05-25 Gilead Pharmasset Llc uso do (2’r)-2’-desoxi-2’-flúor-2’-c-metil nucleosídeo e de uma composição farmacêutica que o compreende
DK1658302T3 (da) 2003-07-25 2010-11-22 Idenix Pharmaceuticals Inc Purinnukleosidanaloge til behandling af sygdomme forårsaget af Flavirividae, herunder hepatitis C
WO2005021007A1 (fr) * 2003-08-28 2005-03-10 Obschestvo S Ogranichennoi Otvetstvennostju 'berezovy Mir' Prevention et traitement de l'hepatite virale b
US7754718B2 (en) 2004-05-05 2010-07-13 Yale University Antiviral helioxanthin analogs
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
MX2007003085A (es) 2004-09-14 2007-08-02 Pharmasset Inc Preparacion de 2'-fluoro-2'-alquilo sustituido u otras ribofuranosil pirimidinas y purinas opcionalmente sustituidas y sus derivados.
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
JP5254033B2 (ja) 2005-12-23 2013-08-07 イデニク プハルマセウティカルス，インコーポレイテッド 分岐型ヌクレオシドを調製するための合成中間体の製造方法
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
DK2012816T3 (da) * 2006-05-02 2012-09-03 Sigma Tau Ind Farmaceuti Anvendelse af Thymosin 1, alene eller i kombination med PTX3 eller Ganciclovir, til behandling af Cytomegalovirus infektion.
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2349315A4 (en) * 2008-10-08 2012-07-04 Univ Miami LYMPHOCYTE REGULATION AND APPLICATION
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
TW201026715A (en) 2008-12-23 2010-07-16 Pharmasset Inc Nucleoside phosphoramidates
JP6104504B2 (ja) 2008-12-23 2017-03-29 ギリアド ファーマセット エルエルシー ヌクレオシド類似体
EP2427213B1 (en) 2009-05-08 2015-04-01 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
CL2011000716A1 (es) 2010-03-31 2012-04-20 Gilead Pharmasset Llc Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
CN103800293B (zh) * 2012-11-09 2015-10-21 长春海悦药业有限公司 一种含有胸腺法新的药物组合物及其制剂
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1216056B (it) * 1988-03-11 1990-02-22 Sclavo Spa Composizioni farmaceutiche contenenti timosina alfa 1.
US5273963A (en) * 1991-03-29 1993-12-28 The George Washington University Compositions and methods for treating small cell and nonsmall cell lung cancers
TW224053B (cs) * 1991-09-13 1994-05-21 Paul B Chretien

Also Published As

Publication number Publication date
DE69219782T2 (de) 1997-10-09
DK0603305T3 (da) 1997-09-01
RO111991B1 (ro) 1997-04-30
CZ286827B6 (cs) 2000-07-12
HU221006B1 (hu) 2002-07-29
US20070218033A1 (en) 2007-09-20
JPH06510998A (ja) 1994-12-08
ATE152914T1 (de) 1997-05-15
NO941310L (no) 1994-04-12
CA2119006C (en) 2005-08-23
AU667327B2 (en) 1996-03-21
RU94022480A (ru) 1996-07-20
HU9400758D0 (en) 1994-06-28
TW224053B (cs) 1994-05-21
GR3024025T3 (en) 1997-10-31
US6001799A (en) 1999-12-14
EP0603305B1 (en) 1997-05-14
FI941133L (fi) 1994-03-10
NO941310D0 (no) 1994-04-12
DE69219782D1 (de) 1997-06-19
FI941133A0 (fi) 1994-03-10
CA2119006A1 (en) 1993-04-01
HK1021687A1 (en) 2000-06-23
RU2104010C1 (ru) 1998-02-10
AU2644792A (en) 1993-04-27
FI107879B (fi) 2001-10-31
EP0603305A1 (en) 1994-06-29
MX9205240A (es) 1993-07-01
CZ55194A3 (en) 1994-10-19
JP3228512B2 (ja) 2001-11-12
KR100254082B1 (ko) 2000-09-01
ZA926964B (en) 1993-04-26
WO1993005806A1 (en) 1993-04-01
HUT75166A (en) 1997-04-28
US5849696A (en) 1998-12-15
ES2103966T3 (es) 1997-10-01

Similar Documents

Publication Publication Date Title
ZA926964B (en) Composition and method of treating hepatitis C.
ZA896864B (en) Method and composition for the treatment and prevention of viral infections
EP0717592A4 (en) METHOD AND COMPOSITION FOR TREATING THE APATHIE DEMOTIVATION SYNDROME
EP0604433A4 (en) Composition and method for disease treatment.
AU3022692A (en) Methods for the treatment of osteoporosis using bone-active phosphonates and parathyroid hormone
GR3022969T3 (en) Products for the treatment of endotoxic shock in a mammal
EP0592569A4 (en) COMPOSITION AND METHOD FOR TRANSDERMAL ADMINISTRATION OF DICLOFENAC.
EP0610444A4 (en) METHOD OF TREATING VIRAL DISEASES.
PL297849A1 (en) Vaccine against and method of treating the patients infectedwith hiv virus
SG46620A1 (en) Method and composition foor the treatment of autoimmune hepatitis
IL104940A0 (en) Method and composition for the treatment of osteoporosis
EP0627930A4 (en) COMPOSITION AND METHOD FOR TREATING HEPATITIS B.
ZA921107B (en) Method of treating Type I diabetes.
GB2271509B (en) Antivenom immunesera
GB9010058D0 (en) Method and composition for the treatment of cancer
MY121198A (en) Method of treating hepatitis c in non-responders to interferon treatment.
EP0452360A4 (en) Methods and compositions for the prophylaxis and treatment of hepatitis b virus infections
ZA929418B (en) Recombinant vaccines and method of producing same.
EP0454169A3 (en) Photomask and method of treating the same
MY110041A (en) Composition and method of treating hepatitis c
ZA947879B (en) Process for the preparation of cyclopentanone mono- or disubstituted in the 2-position
ZA897105B (en) Method and composition for the treatment of viral infections
GB9112552D0 (en) Method and composition for the treatment of cancer
BG98272A (en) Preparation and method for the treatment of virus hepatitis
BG95257A (en) Preparation and method for the treatment of paradontosis